Seize opportunities in obesity care with our in-depth market analysis
DRG Disease Landscape & Forecast
Obesity represents a growing public health challenge across major pharmaceutical markets, with rising evidence of its significant medical and economic burden. Despite widespread prevalence, approved therapies remain limited—particularly in Europe and Japan—creating a substantial unmet need. The development pipeline is expanding, featuring novel agents designed to overcome current treatment limitations by delivering greater, sustained weight loss with improved safety and tolerability.
Obesity/Overweight – Landscape & Forecast – Disease Landscape & Forecast (G7) – This comprehensive report offers in-depth insights into emerging drug targets and expert evaluations of current and pipeline therapies like Wegovy and Zepbound. It provides detailed forecasts of market access dynamics and commercial potential, equipping you with the intelligence needed to navigate opportunities and challenges in the evolving obesity treatment landscape over the next decade.
Request more information
What is Disease Landscape & Forecast?
Disease Landscape & Forecast delivers comprehensive market intelligence combining world-class epidemiology, detailed insights into current and emerging treatment paradigms, and robust drug forecasts supported by thorough primary and secondary research. Updated continuously throughout the year, it ensures timely analysis aligned with key indication-specific developments.
A dedicated Drug Pipeline chapter offers real-time global pipeline intelligence sourced directly from Cortellis, featuring daily updates and interactive, downloadable figures for detailed exploration.
- Extensive market data including epidemiology, therapy insights, and drug forecasts
- Dynamic updates reflecting the latest indication-specific trends
- Real-time, Cortellis-powered pipeline intelligence with interactive analytical tools
Latest developments in obesity treatment:
- Rising public health challenge with limited therapies: Obesity remains a growing public health and economic challenge with limited approved therapies, especially in Europe and Japan.
- Expanding pipeline of novel treatments: The drug development pipeline is expanding with novel agents promising greater, sustained weight loss and improved safety.
- Market opportunity balanced by access restrictions: Significant market opportunity exists, but payer restrictions are expected to limit broad access due to healthcare budget pressures.
- Evolving therapy options and commercial potential: Emerging drug targets and expert insights on current treatments like Wegovy and Zepbound highlight evolving therapy options and commercial potential.
Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.
Key questions answered:
- Which metabolic and central pathways have high potential as drug targets?
- What is the prevalence of obesity in the major pharmaceutical markets under study?
- How is obesity currently treated? What do experts think about Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide) as treatments for obese / overweight patients?
- What is the commercial potential of emerging therapies? How do leaders in the field of obesity management rate these drug candidates?
- How will the obesity therapy market evolve over the next 10 years?
Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.
Key highlights:
10-year market forecast (2023 – 2033)
Annualized detailed forecasts and treatment trends across the U.S., EU5, and Japan.
Granular epidemiological insights
Features prevalence data by country, with diagnosis and treatment rates segmented by population to support targeted market analysis.
Pipeline intelligence powered by Cortellis
Real-time updates on current and emerging therapies, including novel drug classes.
Primary research with 19 country endocrinologists
Specific interviews with thought-leading endocrinologists - experts' perspectives complemented by proprietary survey data from Clarivate broader research initiatives.